In light of the elucidation of the molecular pathogenesis of some dominantly inherited retinal degenerations over the past two decades, it is timely to explore possible means of therapeutic intervention for such diseases. However, the presence of significant levels of intergenic and intragenic genetic heterogeneity in this group of dominant conditions represents a barrier to the development of therapies focused on correcting the primary genetic defect. More than 60 genes have been implicated in dominant retinopathies and indeed over 150 different mutations in the rhodopsin gene alone have been identified in patients with autosomal dominant retinitis pigmentosa. Employing next-generation sequencing to characterise populations of retinal degeneration patients genetically over the coming years will beyond doubt serve to highlight further the immense genetic heterogeneity inherent in this group of disorders. Such diversity in genetic aetiologies has promoted the search for therapeutic solutions for dominantly inherited retinopathies that are independent of disease-causing mutations. The various approaches being considered to provide mutation-independent therapies for these dominant conditions will be discussed in the review, as will the preclinical data supporting the further development of such strategies.
INTRODUCTION
The era of genomics has enabled the elucidation of the genetic aetiologies of many inherited conditions. Indeed, this evolution in technologies has greatly facilitated investigation of the molecular pathogenesis of inherited retinal degenerations, from the localisation of the first disease-causing gene to chromosome Xp11.3 utilising genetic linkage mapping almost three decades ago, 1 to the application of next-generation sequencing technologies to enable rapid identification of disease-causing mutations in known and candidate disease genes for populations of retinal degeneration patients. 2 Exome and whole genome sequencing will over the next few years move the dissection of the molecular genetics of these conditions to a new level. 3 It could be argued that the overwhelming finding thus far from this enormous body of research is the significant level of genetic heterogeneity inherent in many inherited conditions. Undoubtedly, whole exome sequencing will only serve to further highlight that disorders which are categorised together based on similarities in clinical presentation, when dissected at the molecular level, are extremely genetically heterogeneous involving multiple genes and indeed multiple disease-causing mutations within individual genes. In this regard, autosomal dominantly inherited retinal degenerations demonstrate both significant intergenic and intragenic genetic heterogeneity, with over 60 genes implicated in these disorders (www.sph.uth.tmc.edu/ RetNet) and over 150 mutations identified to date just within a single disease-causing genes, the rhodopsin gene (RHO) (www.hgmd.cf.ac. uk/ac/index.php). The presence of such enormous levels of genetic heterogeneity in many Mendelian disorders and indeed recently emerging for many multifactorial disorders, presents significant obstacles in the development of gene-based therapies for such disorders. In this review, we will discuss the various strategies that are being pursued to develop therapies for the heterogeneous group of conditions that are broadly termed dominantly inherited retinopathies.
Although the availability of accurate information on the genetic aetiology of disease underpins the rationale behind designing therapies targeted towards the primary genetic defect, for some families with a dominantly inherited disease, the mutation is sufficiently rare that the family has almost its own 'personal mutation' . The observation of such a phenomenon in many dominantly inherited conditions (http:// www.ncbi.nlm.nih.gov/omim; Table 1 ) has prompted the exploration of strategies to overcome this mutational diversity in disease aetiology. Broadly such therapeutic strategies fall into two categories, those targeted towards correcting the primary genetic defect and those targeted towards modulating the effects associated with the presence of the genetic defect and encoded mutant protein; an overview of both these approaches will be provided in this review.
THERAPIES TARGETED TO CORRECTING THE PRIMARY GENETIC DEFECT FOR DOMINANTLY INHERITED RETINOPATHIES
An example of a dominantly inherited disorder for which both of the broad therapeutic approaches referred to above are being pursued, is autosomal dominantly inherited, RHO-linked retinitis pigmentosa (RHO-adRP), an untreatable retinal degeneration involving the progressive death of photoreceptors leading to significant visual dysfunction. 4 ,5 RHO-adRP is the most common form of retinitis pigmentosa (RP) accounting for 25-30% of cases of autosomal dominant RP (adRP), but with over 150 different disease-causing mutations in RHO, there is tremendous genetic heterogeneity. The cellular mechanisms leading to photoreceptor cell degeneration can vary considerably and indeed for many mutations have not been fully elucidated. 6 To circumvent the mutational heterogeneity, a mutation-independent therapy targeting the primary genetic defect is being explored. The approach involves the use of two components, suppression of both mutant and wild-type RHO alleles and provision of a suppression-resistant replacement RHO gene, engineered using codonredundancy. [7] [8] [9] [10] [11] [12] [13] [14] In the context of dominant retinopathies, suppression and replacement is also being explored as a therapy for peripherin/ retinal degeneration slow-linked adRP, the next most common form of adRP after RHO-adRP. 15, 16 In principle, replacement genes could be modified in a number of ways, for example, at degenerate sites as stated above. Alternatively, modified UTRs could be incorporated in replacement genes or intragenic polymorphisms may be employed such that transcripts from replacement genes are refractory to suppression 7 or altered promoters may be used when suppressors are targeted to promoter DNA sequences. 14 In summary, suppression and replacement may provide a way of correcting the primary genetic defect, and will be relevant particularly where the presence of a mutant protein drives the disease process.
SUPPRESSION OF GENE EXPRESSION-MOLECULAR TOOLS
Although the principle of gene suppression and gene supplementation, whether in combination or alone, depending on the mode of action of a particular dominant mutation, should provide therapeutic solutions for many dominant conditions, various molecular tools are required to enable the successful development of such therapies. One challenge has been the availability of potent methods for suppression of gene expression. Until a decade or so ago, the methodologies available for gene suppression such as antisense RNA and DNA 17 and ribozymes 18 (autocatalytic RNA enzymes), typically lacked potency once transferred from an in vitro to an in vivo setting. Hence, a significant step forward in terms of the potency of gene suppression in vivo was provided by the seminal discoveries of Andrew Fire and Craig Mello in 1998 working with C. elegans. 19 Using double-stranded RNA targeting a number of genes in nematode worms, they demonstrated that the potency of double-stranded RNA was significantly greater than that of single-stranded antisense RNA. They termed this phenomenon RNA interference (RNAi). Notably, the team had uncovered not only a powerful technology for gene suppression, but the endogenous cellular machinery, from worms to mammals, involved in processing a range of non-coding RNAs. Such non-coding RNAs have subsequently been found to have roles in control of gene expression, stem cell differentiation, cellular homeostasis and maintenance of chromatin structures, among others. 20, 21 Components of the cellular machinery that orchestrate RNAi have now been identified including components of the RNA-induced silencing complex such as the argonaute proteins employed as 'molecular scissors' to cleave RNA target transcripts; cleaved transcripts are subsequently subjected to RNase-mediated degradation ( Figure 1 ). 22 By using either synthesised double-stranded RNA or double-stranded RNA expressed from plasmid or viral vectors, the cellular machinery can be recruited to orchestrate potent suppression of a target gene in a sequence-specific manner as outlined in Figure 1 . RNAi has now been used to achieve potent gene suppression of a variety of genes implicated as causative of inherited dominant retinopathies as detailed below. In principle, RNAi could be utilised to silence genes directly causative of a dominant condition or genes whose encoded products elicit secondary effects, which serve to exacerbate the disease pathology.
The repertoire of molecular agents available to achieve sequencespecific gene suppression is increasing as novel technologies emerge. Such suppression agents can not only be targeted to RNA transcripts as is the case with antisense, ribozymes and RNAi, but can include targeting DNA and proteins using zinc-finger proteins (ZFPs), oligonucleotides to induce DNA correction, aptamers and antibodies among other methodologies. [23] [24] [25] [26] For example, DNA-binding ZFPs can be used (alone or in conjunction with endonucleases for DNA cleavage) to bind specific DNA targets. In principle, binding of ZFPs to 5¢ promoter sequences can thus be utilised to suppress expression of a target gene. Indeed, ZFPs can be used to induce or repress gene expression by attaching ZFPs to enhancer or repressor molecules. 27 In essence, designer peptides incorporating DNA-binding domains consisting of tandem zinc fingers to facilitate DNA binding can be characterised from libraries of ZFPs. Recently, this technology has been used to identify potent ZFPs to suppress expression of human RHO as detailed below. 14 It is clear that the past decade has provided innovative molecular tools to elicit potent gene suppression, which may be applied to the modulation of genes causative of dominant retinal dystrophies.
AAV-MEDIATED DELIVERY FOR SUSTAINED GENE SUPPRESSION
The nature of progressive neurodegenerations, such as RP, demands a solution involving sustained expression of the therapy. One of the key challenges associated with the development of gene-based medicines for any target tissue has been development of suitable, immunetolerated vectors to carry the gene therapy cargo to the target cells. In this regard, adeno-associated virus (AAV) is a particularly attractive choice of vector for the retina as it elicits minimal immunogenicity. A variety of naturally occurring AAV serotypes and artificially evolved AAV vectors using, for example, capsid shuffling to generate chimeric capsids, have become available for gene delivery. 28 Indeed, a number of AAV serotypes have been shown to transduce retinal cell types efficiently, for example, AAV2/5 and AAV2/8 preferentially infect photoreceptors whereas AAV2/4 is restricted to the retinal pigment epithelium. 29, 30 In addition, AAV2/9 has been found to enable gene delivery after systemic administration to many tissues including brain and retina. 31, 32 Another attractive feature of AAV as a vector is its predilection to remain episomal particularly in the context of postmitotic cells such as photoreceptors thereby reducing the risk of insertional mutagenesis. Results from recent human clinical trials for a severe recessively inherited retinopathy, retinal pigment epithelium-65-linked Leber congenital amaurosis, have served to highlight the attractive features of AAV as a delivery vector for the human eye. [33] [34] [35] [36] [37] Notably, in three Leber congenital amaurosis trials reported to date AAV2/2 vectors have been well tolerated after a single subretinal administration of vector (with doses ranging from 1.5Â10 10 -1.5Â10 11 viral particles per treated eye) and moreover have provided beneficial effects to the function of the treated eye as evaluated by a range of methods including retinal sensitivity to light and patient mobility. The majority of AAV serotypes, while providing many advantageous features, have a limited packaging capacity of approximately 4.5 kb currently restricting their use to therapies requiring a relatively modest cargo size. In this regard, technologies that facilitate efficient transgene reconstitution from two separate AAV vectors may extend AAV capacity, 38 in principle bringing disorders whose causative genes are greater than 4.5 kb under the AAV umbrella. It is clear that for dominant disorders such as RHO-adRP and retinal degeneration slow-adRP, sustained suppression of the mutant gene driving the disease process will likely be required. Hence, attention has been focused on suppressors delivered by vectors, such as AAV, rather than using synthesised suppressor molecules whose longevity of action is typically rather transient.
PRECLINICAL STUDIES USING THERAPIES TARGETING THE PRIMARY GENETIC DEFECT
As outlined above, both potent suppression agents and immunetolerated viral vectors with good safety profiles in humans are now available for gene delivery to the retina and hence it is timely to explore the application of these technologies to provide therapeutic solutions for autosomal dominantly inherited retinopathies including Figure 1 RNAi pathways. The microRNA (miRNA) pathway is initiated by endogenously expressed primary miRNA transcripts (pri-miRNAs), which are transcribed by RNA polymerase II (PolII) and processed by the enzyme complex Drosha, converting pri-miRNAs to precursor miRNAs (pre-miRNAs). These are transported from the nucleus to the cytoplasm by Exportin 5 where pre-miRNAs are bound to Dicer, a ribonuclease-III family member, and then complexed with the Argonaute 2 (AGO2)-RNAi-induced silencing complex (RISC). Here, the sense strand is unwound enabling the mature miRNA to recognise target sites in mRNA sequences (usually within the 3¢UTR) and inhibit translation. Additionally, the binding of miRNAs to target mRNAs may cause mRNA degradation in processing (P)-bodies. The small interfering RNA (siRNA) pathway is initiated by the cleavage of double-stranded RNA by Dicer into siRNA, which similarly to pre-miRNA, is then incorporated into the AGO2-RISC complex. AGO2 cleaves the sense strand so that the singlestranded antisense strand may recognise target sites and direct sequence-specific cleavage by AGO2 of target mRNA. Provided with permission from de Fougerolles et al. 22 those listed in Table 1 . Suppression and replacement, while an attractive solution to circumvent the extensive mutational heterogeneity observed in many dominantly inherited conditions, involves a two component therapeutic. Such a dual component gene-based medicine will require considerable optimisation of each of the individual components of the therapy to ensure that potent suppression of the target gene in parallel with appropriate levels of expression of the replacement gene are achieved, in order to provide therapeutic benefit. Despite the obvious challenges, significant advances have been made with regard to the treatment of RHO-adRP using RNAi and ribozyme-based suppression of RHO in conjunction with a RHO replacement gene engineered to be refractory to suppression via the introduction of nucleotide changes at degenerate positions over the target sites for suppression. 7-14 AAV2/5-mediated RNAi-based suppression of RHO has been found to provide benefit in the P347S mouse. 39 This mouse carries a human RHO transgene bearing a P347S mutation and simulates human RHO-adRP. Following a single subretinal injection with AAV2/5 expressing an RNAi suppressor targeting only the human RHO transgene, the thickness of the outer nuclear layer was over twofold greater than in fellow control eyes. Similarly, 10 weeks post-injection electroretinography responses were 2-3-fold greater. Notably, two copies of the endogenous murine Rho gene, which were resistant to RNAi suppression because of sequence differences between the human and mouse genes, provided functional RHO. RNAi molecules have been shown to suppress human RHO by approximately 90% in transduced photoreceptor cells. 12 Using the same P347S murine model of RHO-adRP, a ZFP (expressed from an AAV vector) targeting the RHO promoter has also been shown to provide benefit by suppression of the mutant P347S RHO, again in conjunction with expression of the endogenous mouse RHO gene. 14 It is worth highlighting that an additional challenge, particularly relevant to RHO-adRP, is associated with the substantial levels of endogenous RHO expression present in mammalian rod photoreceptors. Indeed RHO protein, one of the first G-protein-coupled receptors to be characterised, comprises 90% of the protein of the rod photoreceptor outer segment disc membranes. Recapitulating such high levels of expression from an AAV vector in the human retina represents a key challenge associated with potential future clinical trials for RHO-adRP employing the approach of suppression and replacement. In this regard, it is of note that functional rescue of a murine RHO knockout mouse (RhoÀ/À null mouse 40 ) has been achieved using an AAVdelivered chimeric RHO promoter-driven human RHO replacement gene. 41 Notably, significant optimisation of the promoter was required in order to achieve sufficient levels of RHO expression to provide functional benefit in this model. However, benefit did not persist over time possibly because mouse pups, injected at P0, received small volumes of virus (0.5 ml) and additionally viral spread was in the order of 30-40%. Furthermore, significant histological and electrophysical benefit has been demonstrated in the P347S mouse model of RHOadRP by combining suppression and replacement in a single administration of two AAV2/5 vectors, one with an RNAi suppressor and the other providing a codon-modified RNAi-resistant RHO replacement gene ( Figure 2 ). 13 At 20 weeks post-injection, some control eyes gave vestigial rod-isolated electroretinography responses and the outer nuclear layer had almost completely disappeared. In contrast, 3-4 rows of photoreceptor nuclei remained in the outer nuclear layer of eyes treated with the dual component therapy and rod-isolated electroretinography responses of approximately 60 mV were recorded. The principle of suppression and replacement will likely be applied in the development of therapies for other diseases both within and beyond the field of inherited retinal degenerations. Alternative therapeutic options for some dominant conditions include selective suppression of expression of the mutant allele, an approach that has been pursued for some genes including Ataxin-3 Figure 2 Rescue of photoreceptor cell morphology following treatment with combined suppression and replacement gene therapy. P347S mice have a photoreceptor cell degeneration similar to dominant RP. (a) In 6-week-old mice, rod photoreceptor inner segments (IS) are attached to truncated outer segments (OS) with disorganised disks. Five-day-old mice received subretinal injections containing a mixture of two different AAV vectors expressing either a RHO suppressor and an EGFP marker gene (AAV-S) or a RHO replacement gene (AAV-R). At 6 weeks (b) and 20 weeks (c) post-injection, eyes were fixed, whole mounted and transduced areas, identified by EGFP fluorescence, excised. Excised retinal samples and untreated control (Ctr) retinal samples were processed for transmission electron microscopy (TEM). Rod photoreceptor cells in treated samples had distinct OS with correctly formed membrane disks (b, c) in contrast to control retinas (a). CC, connecting cilium. Bars¼500 and 100 nm (inserts). Provided with permission from Millington-Ward et al. 13 and Huntingtin involved in Machado-Joseph disease and Huntington's disease, respectively. 42 Indeed, before the exploration of suppression and replacement therapies, the strategy that was considered for dominantly inherited disorders typically involved selective suppression of the mutant allele. Such an approach for a dominantly inherited disorder becomes attractive if there is one or more commonly observed disease-causing mutation(s) where the affected patient population is significant in size. Although there are some technical difficulties associated with designing allele-specific suppressors that can achieve allele discrimination at the level of a single nucleotides, it is in principle possible and has been achieved, for example, for the cancer gene, K-RAS, and for APP that is involved in Alzheimer's disease. 43, 44 With regard to dominant retinopathies, mutation-specific/allele-specific approaches for RHO-adRP have been adopted utilising ribozymes 45 and RNAi; 46 the former study employing ribozymes achieved more optimal allele-specific silencing, largely due to the nature of the suppressor. The absolute requirement of an NUX site (as defined by N¼any nucleotide, U¼Uracil and X¼any nucleotide except G) at the site of ribozyme cleavage, 47 in principle provides a suppressor that can achieve a binary sequence-specific discrimination at the level of a single nucleotide. More specifically, providing that the nucleotide difference between the mutant and wild-type alleles occurs at either the U position or involves a G at the X position of a targeted NUX ribozyme cleavage site, only the mutant sequence should be cleaved. Of course many disease mutations do not fall in the correct position at an NUX ribozyme cleavage site and moreover, translating the efficiency of ribozyme cleavage achieved in vitro to an in vivo setting has been disappointing. Therefore, at present, mutation-specific suppression strategies may have rather limited applications in the development of treatments for dominantly inherited retinopathies.
In addition to the features outlined above, the mode of action of the disease-causing mutation will in part determine the most appropriate therapeutic approach for the particular dominantly inherited conditions. For some dominant disorders, the associated pathology may be caused by the presence of the mutant protein (via a gain of function or dominant-negative mechanism) in other instances it may be due to haploinsufficiency or indeed by a combination of both mechanisms. 48 In situations where at least some of the disease phenotype results from reduced levels of wild-type protein, delivery of the wild-type gene in the absence of suppression of the mutant allele may potentially provide benefit. In this regard, Mao et al. 49 have delivered the wildtype RHO gene to P23H Rho+/+ mice and obtained some histological and electroretinographic benefit at 6 months post-injection benefit. The thickness of the outer nuclear layer of treated eyes was 80% greater than of control eyes and A-and B-wave amplitudes were increased by 100% and 79%, respectively. However, benefit following gene delivery of a RHO gene was not observed in a different murine model for RHO-adRP, the P347S mouse. 13 In contrast to the scenario outlined above, there may be some dominantly inherited disease pathologies where the wild-type protein is not required for the survival and functionality of fully differentiated mature neurons, such as photoreceptors. Indeed, for such disorders suppression alone may provide a potential therapeutic strategy, that is, suppression of both wild-type and mutant alleles, representing a mutation-independent therapy. One example of a dominant retinopathy that may fall into this category is IMPHH1-linked adRP (IMPDH1-adRP). This is a relatively severe form of RP and yet the Impdh1 knockout mouse (Impdh1À/À mouse) presents with an extremely mild phenotype 50 suggesting that absence or reduced levels of IMPDH1 may be tolerated in the context of the mammalian retina. Therefore, for IMPDH1-adRP, a mutation-independent 'suppression only' strategy may potentially provide benefit as demonstrated at the histological level in an AAV-induced mouse model of IMPDH1-adRP. 51 In this study, AAV2/ 5-delivered mutant IMPDH was shown to induce a retinopathy in mice akin to RP. However, when co-injected with a second AAV expressing an siRNA targeting IMPDH, the outer nuclear layer thickness of co-injected mice at 4 weeks post-injection resembled wild-type outer nuclear layer thicknesses. It is of note that for many dominantly inherited mutations, the precise mode of action remains to be fully elucidated, representing an additional complication in the development of therapies for such disorders. It is clear that further elucidation of the modes of action of dominantly inherited mutations and their downstream effects may provide additional novel pathways for therapeutic development. The modulation of such pathways may potentially provide beneficial effects as outlined in the section below.
PRECLINICAL STUDIES USING THERAPIES MODULATING SECONDARY EFFECTS ASSOCIATED WITH DISEASE PATHOLOGY
Alternative therapeutic approaches for autosomal dominantly inherited retinopathies focused on modulating secondary effects associated with the disease are being explored in parallel with therapies focused on correcting the primary genetic defect. Indeed, the approaches under consideration for retinopathies typically mirror those being explored for a range of other neurodegenerative disorders. 52 Although the era of genomics continues to highlight diversity in the genetic aetiology of many inherited conditions, there has been a simultaneous realisation that in many neurodegenerative disorders, disease mechanisms may converge, providing an opportunity for synergy in terms of designing new treatments. Therapies under consideration for many neurodegenerative conditions include the provision of neurotrophic factors to extend longevity of neurons, the modulation of oxidative stress known to damage and reduce neuronal survival, the provision of anti-apoptotic factors to modulate apoptotic pathways, which may be inappropriately invoked in degenerating neurons and the modulation of the cellular response to the presence of aggregated proteins, a damaging insult for neurons among others. [53] [54] [55] [56] The examples provided in this review are by no means exhaustive, but provide an overview of these emerging fields in relation to dominantly inherited retinal degenerations. For example, therapeutic benefit in rodent models of adRP has been demonstrated using a variety of neurotrophic factors including rod-derived cone viability factor (RdCVF), 53 ciliary neurotrophic factor, 57 glial-derived neurotrophic factor 58, 59 and members of the family of fibroblast growth factors, 60 among others. However, typically the rescue achieved using such factors has been rather transient in nature. Modes of delivery of neurotrophic factors have varied from local delivery via subretinal injection of protein 53 or vectors expressing neurotrophic factor genes [57] [58] [59] to transplantation of gene-modified stem cells overexpressing a neurotrophic factor such as glial derived neurotrophic factor 60 or implantation of intraocular polymer encapsulated cell technology devices delivering cells, which overexpress ciliary neurotrophic factor. 61 Indeed, initial indications of the possible benefits that could be accrued from delivery of neurotrophic factors for dominant retinopathies were observed in the Q344ter murine model of RHO-adRP 62 and a feline model of an autosomal dominant rod-cone dystrophy 63 (the Rdy cat-subsequently identified as CRX-linked adRP) as early as 1998 and 1999, respectively. Although results with some of these neurotrophic factors remain encouraging, for any particular neuroptrophic factor, the route of administration, the ability to confine the therapy to the target cell type together with tight control on dose given the possible pleiotropic effects of the therapies, will undoubtedly determine the efficacy of such therapies in human patients. For example, possible cytotoxic dose-related effects have been observed in preclinical studies with ciliary neurotrophic factor. 64, 65 An alternative therapeutic approach relevant to dominant retinopathies under consideration is the modulation of oxidative damage in the degenerating retina. As rod photoreceptor cells die in a retina undergoing a progressive rod-cone dystrophy, remaining cone photoreceptor cells may be subjected to increasing levels of oxygen promoting oxidative damage to cones. In this regard, the Q344ter murine model of RHO-adRP has been treated with cocktails of antioxidants injected daily between P18-P35 and a 2-3-fold increase in cone photoreceptor cell density was observed in treated versus control eyes assessed at P35. 66 Antioxidant molecules under investigation for therapeutic effects have included a-tocopherol, ascorbic acid and alipoic acid delivered as antioxidant cocktails. Alternatively, a transgenic approach has been used to achieve overexpression of Gpx4 and Gpx1. 67 Similarly, modulation of NADPH oxidase (Nox) using the Nox inhibitor apocynin has also been shown to protect against oxidative stress in the Q344ter RHO-adRP mouse. 68 Clearly many linkages between the neurotrophic and antioxidant approaches will exist, as aptly demonstrated by RdCVF. RdCVF is a thioredoxin-like protein that mediates resistance to photo-oxidative damage and has been shown to protect cone photoreceptors in the rd1 mouse 69 and the P23H rat. 70 Indeed, cone numbers were 20% higher in treated versus untreated eyes and photopic b-waves increased by over 100% in 9-month old rats. Furthermore, recent evidence of interactions between RdCVFL, an alternatively spliced polypeptide produced from the Nxnl1 gene, which also expresses RdCVF, and the pathways involved in oxidative damage in neurons has been obtained. 71 Similarly, overexpression of the antioxidant protein thioredoxin in transgenic tubby mice, a model for Usher syndrome type 1, has been found to be neuroprotective in the degenerating murine retina and resulted in among other effects upregulation of neurotrophic factors including brain derived neurotrophic factor and glial derived neurotrophic factor, activation of the Akt and Ras/Raf1/ERKs survival signal transduction cascade and inhibition of the ASK1/JNK apoptosis pathway. 72 Although neurotrophic factors and antioxidants represent potential future therapeutics for dominantly inherited retinal dystrophies, additional approaches are being considered such as modulation of the cellular events accompanying the presence of increasing levels of aggregated proteins in some neurodegenerative disorders. 73 In this regard, a number of mutations causative of autosomal dominantly inherited retinal degenerations involve protein mis-folding leading to protein aggregation, cellular toxicity and ultimately apoptosis; indeed it is believed that many RHO mutations may operate in this manner. Similar observations have been made previously for other neurodegenerative disorders including Alzheimer's disease, Parkinson's disease and Huntington's disease, among others. 74, 75 A variety of approaches may facilitate the chaperoning of mis-folded proteins and thereby modulate the unfolded protein response. Recently with regard to dominant retinopathies, AAV-mediated overexpression of a chaperone, Grp78/BiP, has been shown to provide preserved photoreceptor function in P23H RHO-adRP rats. 76 Interestingly, in this study the preservation of photoreceptor cell function was thought not to result from increased levels of RHO folding, but due to a BiP-induced reduction in apoptosis. Small molecule chaperones have also been explored, for example, 17-AAG, an inhibitor of heat shock protein-90 and an inducer of heat shock protein-70 was found to be protective in an AAV-induced mouse model of IMPDH1-adRP, resulting from a build-up of aggregated mutant IMPDH1 protein. 77 The therapeutic effect(s) of 17-AAG for IMPDH1-adRP were augmented by increasing the bioavailability of this small molecule drug in the retina by transiently opening the blood retinal barrier with RNAi molecules targeting a tight junction protein, Claudin-5(BRB). 77 
CONCLUDING REMARKS
Many additional therapeutic strategies relevant to dominantly inherited retinal degenerations such as cell transplantation and retinal chip devices are currently being pursued, which due to space constraints have not been discussed in this review. However, it is beyond doubt, given the therapeutic approaches reviewed above, that significant strides towards the development of therapies for dominant retinopathies involving either correction of the primary genetic lesion or targeted towards secondary effects associated with the presence of the mutant gene have been made over the past few years. It does, however, remain to be established if at times multivalent therapies involving a combination of strategies may be required to protect photoreceptor neurons amply from a degeneration precipitated by the presence of dominant mutations. Furthermore, the full extent of the genetic heterogeneity inherent in groups of conditions such as autosomal dominantly inherited retinal degenerations remains to be elucidated; associated investigations will be greatly facilitated by whole exome sequencing. The conclusions from such future studies may be that a proportion of autosomal dominantly inherited retinopathies are individually so rare that 'designer' therapies for each of them will not be economically possible and hence therapies targeted towards convergent features between such disorders may represent more realistic therapeutic strategies.
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